Sensor-augmented CSII therapy with predictive low-glucose suspend following total pancreatectomy.

Area of Science:

• Endocrinology
• Metabolic Disorders
• Surgical Oncology

Background:

• Pancreatogenic diabetes results from endocrine and exocrine dysfunction, often following pancreatectomy.
• Recurrent severe hypoglycemia is a significant complication in pancreatogenic diabetes.
• Current management guidelines for pancreatogenic diabetes are lacking.

Purpose of the Study:

• To describe the post-operative management of pancreatogenic diabetes in two patients after total pancreatectomy.
• To evaluate the efficacy of sensor-augmented continuous subcutaneous insulin infusion (CSII) with predictive low-glucose suspend in managing pancreatogenic diabetes.
• To demonstrate the potential of continuous glucose monitoring (CGM) technology in averting hypoglycemia and improving quality of life.

Main Methods:

• Case study of two patients with pancreatogenic diabetes post-total pancreatectomy.
• Management with sensor-augmented predictive low-glucose suspend continuous subcutaneous insulin infusion (CSII).
• Monitoring of glycemic control and hypoglycemic events.

Main Results:

• Sensor-augmented CSII successfully averted severe hypoglycemia in both patients.
• Optimized glycemic control was achieved with the implemented CSII system.
• Continuous glucose monitoring (CGM) technology demonstrated effectiveness in preventing hypoglycemia.

Conclusions:

• Predictive low-glucose suspend technology combined with CGM offers excellent glycemic control while preventing severe hypoglycemia in pancreatogenic diabetes.
• Sensor-augmented CSII is a viable therapeutic option for managing pancreatogenic diabetes post-pancreatectomy.
• This approach can improve quality of life and reduce diabetes-related complications.